Lab and R&D software, scientific data platforms, LIMS/ELN, AI for drug discovery and biotech SaaS.
Every story from Software in Science, newest first.
Agents now run whole R&D workflows, with scientists approving key steps. Benchling calls agents its fastest-growing product.
Read the full story →AI turns plain-English SOPs into GxP-ready workflows from research to production, shipping in December.
Read the full story →Drug-programme coordination agents are being folded into OpenAI’s Rosalind life sciences suite. The AI labs are now chasing R&D software budgets.
Read the full story →The chemistry R&D platform grew users 6x year on year, with partners including BASF, Henkel and Clorox.
Read the full story →Two of Q3’s three biggest rounds went to AI drug developers: Chai Discovery ($400M) and Enveda ($311M). Investors are concentrating big cheques in fewer, later-stage companies.
Read the source →Dan Rizzo is now EVP Sales, Consulting & Services. Tom Schwenger has left to become CEO of a Veeva partner.
Read the full story →Carl Raimond, formerly President of Proteomic Sciences at Thermo Fisher, is the new CEO.
Read the full story →Casimir Starsiak III, formerly Eli Lilly’s enterprise AI and research software lead, is the new CEO.
Read the full story →Jack Maclean specialises in Life Science Software hiring at QP Group. Talk to Jack about the market, salaries or a search.
The full archive of Software in Science.
A three-minute weekly read: funding, launches, leadership moves and what they mean for hiring. Written by Jack Maclean. No spam, one-click unsubscribe.
